An FDA advisory committee voted 8-6 to recommend allowing pharmacy compounding of unapproved peptides like BPC-157, raising urgent questions about patient safety, telehealth marketing practices, and regulatory integrity.
Source: santafenewmexican.com · texarkanagazette.com
Biopharma companies watch as the Safe Drugs Act proposes to force large compounding pharmacies under FDA manufacturing standards, potentially curtailing compounded GLP‑1 copies that have capitalized on brand‑name shortages. The regulatory shift could favor innovators like Novo Nordisk and Eli Lilly, reshape the competitive landscape, and alter the risk‑reward calculus for obesity‑focused pipelines.
Source: vtcng.com · sanfordherald.com